Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Karyopharm Therapeutics (KPTI) PT Lowered to $20 at Wedbush
August 4, 2020 1:44 PM EDTWedbush analyst David Nierengarten lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $20.00 (from $26.00) while maintaining a Neutral rating.
... MoreKaryopharm Therapeutics (KPTI) Misses Q2 EPS by 5c, Revenues Beat
August 4, 2020 7:22 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.63), $0.05 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $33.51 million versus the consensus estimate of $27.42 million.
"Despite the ongoing global COVID-19 pandemic, Karyopharm was able to achieve record quarterly XPOVIO sales as well as execute on several important initiatives, including receiving approval of XPOVIO for its second cancer indication from the U.S. Food and Drug Administration (FDA) to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). XPOVIO is now the only single-agent oral therapy approved in this... More
